A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

To join this study, you must have been diagnosed with multiple myeloma and have already tried at least three different types of treatment, including two specific kinds of drugs (called a proteasome inhibitor and an immunomodulatory drug). Alternatively, your cancer might be considered 'double refractory,' meaning it hasn't responded well to those two specific types of drugs.

Doctors will need to confirm that your multiple myeloma can be measured, either in your blood or urine. You also need to be generally well enough to take part, as assessed by a doctor. If you're a woman who could become pregnant, you'll need to have a negative pregnancy test before starting the study drugs.

If you join this study, you'll go through several stages. First, there's a 'screening period' where doctors will check if you're suitable to take part. After that, you'll enter the 'treatment period.' This involves two main parts: first, a dose-finding stage to figure out the best amount of medication, and then a stage where more people receive the chosen dose. You'll receive the study drugs according to a schedule decided by the research team.

After your treatment finishes, there will be a 'post-treatment follow-up period' lasting up to 16 weeks to monitor your health. Some participants who are still benefiting from the treatment might be able to continue into a 'long-term extension period.' The study is expected to last about five and a half years in total. During this time, you'll have regular hospital visits for assessments, including blood tests and other checks, to monitor how you're responding to treatment and manage any side effects. The exact number of visits will be explained by the study team.